Techno Drugs Ltd. announcements
59 Dhaka Stock Exchange announcements for Techno Drugs Ltd. (TECHNODRUG) since 2024: results, dividends, board meetings, AGMs, record dates and other price-sensitive information. Showing 2026 (22).
- Dividend Declaration
The Board of Directors has recommended 10% Cash Dividend, only for the General Shareholders Excluding Board of Directors and Sponsors for the year ended June 30, 2026. The number of securities held by the sponsors/directors who will not be entitled to the recommended dividend is 82,776,200. The total amount payable to the entitled general shareholders as dividend is Tk. 49,221,988. Date of AGM: 24.12.2026, Time: 10:00 a.m., Venue: The AGM will conducted through Hybrid System in combination (cont.1) (Cont. news of TECHNODRUG): The Company has also reported EPS of Tk. 1.51, NAV per share with revaluation of Tk. 31.71, NAV per share without revaluation of Tk. 28.02 and NOCFPS of Tk. 2.66 for the year ended June 30, 2026 as against Tk. 1.76, Tk. 30.58, Tk. 26.88 and Tk. 1.43 respectively for the year ended June 30, 2025. (end) (Cont. news of TECHNODRUG): of Digital Platform through the https://technodrug.hybridagmbd.net and Physical Presence at Institution of Diploma Engineers, 160/A, Kakrail VIP Road, Dhaka 1000. Record Date: 19.11.2026. (cont.2)
- Price Limit Open
There will be no price limit on the trading of the shares of the Company today (29.10.2026) following its corporate declaration.
- Board Meeting schedule under LR 19(1)
As per Regulation 19(1) of the Dhaka Stock Exchange (Listing) Regulations, 2015, the Company has informed that a meeting of the Board of Directors will be held on October 28, 2026 at 4:00 PM to consider, among others, annual audited financial statements of the Company for the year ended June 30, 2026.
- Further Clarification on News Published in Newspaper/Online Portal
Refer to their earlier news disseminated by DSE on 07.10.2026 regarding clarification on recent news published in the online news and further query issued by DSE on October 13, 2026, the company has further informed, among others, the following: "...We did not publish a separate dissemination notification. This omission was purely unintentional. Mentionable that Our company primarily manufactures and supplies pharmaceutical items, specifically contraceptive (birth control) products, (cont.) (Cont. News of TECHNODRUG): which are historically sold through government tender processes. Over the last two years, sales through government tenders were temporarily halted, which severely impacted our cash flow and led to a delay in servicing our bank loan interest. Of the total interest amount of BDT 21.78 Crore, we have repaid BDT 8.80 Crore, leaving an overdue balance of BDT 12.98 Crore. Furthermore, we were unaware that the bank had initiated the auction process at that stage..." (end)
- Clarification on recent news published in the online news
In response to a DSE query letter dated October 06, 2026 regarding a news published in an online news titled "Techno Drugs' main factory up for auction, Tk. 203 crore in loan default (translated from Bengali to English)" on October 05, 2026, the company has informed the following: "Our company operates two manufacturing facilities located in Gazipur and Narsingdi. A significant portion of our manufactured (cont.1) (Cont. news of TECHNODRUG): Production activities across our factories remain operational. We anticipate that once the tender process resumes, the company's revenue stream and banking operations will swiftly normalize. We assure our valued shareholders, investors, and the DSE authorities that the management is taking all necessary and effective steps to resolve this temporary loan-related challenge at the earliest." (end) (Cont. news of TECHNODRUG): was recently published in Daily Samakal. Please be informed that the management takes this matter with utmost seriousness. We are actively engaged in advanced bilateral negotiations with the bank to resolve the issue through by pay Cheque for loan Adjustment. (cont.3) (Cont. news of TECHNODRUG): medicines specifically Contraceptive (Birth Control) products has historically been sold through government tender processes. In the previous year, sales through Government tenders were temporarily halted, which adversely impacted the company's expected cash flow. As a consequence, there was a temporary delay in servicing our regular bank loan installments. Due to the delay in installment payments, the respective bank issued a notice, which (cont.2)
- Auditor's report regarding status of IPO Proceeds utilization
Techno Drugs Limited submitted auditor's report regarding status of IPO (Initial Public Offering) Proceeds utilization statement for the Quarter ended on 30 June 2026. To view the details, please visit: https://www.dsebd.org/Auditors_opinion/Techno%20Drugs826.pdf
- Credit Rating Result
Emerging Credit Rating Limited (ECRL) has assigned Surveillance rating of the Company as "BBB" in the long term and "ST-3" in the short term along with a Stable outlook based on audited financial statements up to June 30, 2025, quarterly unaudited financial statement up to March 31, 2026, and other relevant quantitative as well as qualitative information up to the date of rating.
- Resumption after Record Date
Trading of the shares of the company will resume on 11.06.2026.
- Suspension for Record Date
Trading of the shares of the company will remain suspended on record date i.e., 10.06.2026 for EGM.
- Spot for EGM
Trading of the shares of the company will be allowed only in the Spot Market and Block transaction will also be settled as per spot settlement cycle from 08.06.2026 to 9.06.2026 and trading of the shares will remain suspended on record date i.e., 10.06.2026 for EGM.
- Auditor's report regarding status of IPO Proceeds utilization
Techno Drugs Limited submitted auditor's report regarding status of IPO (Initial Public Offering) Proceeds utilization statement for the quarter ended 31 March, 2026. To view the details, please visit: https://www.dsebd.org/Auditors_opinion/Techno%20Drugs%20Limited26.pdf
- Decision to hold EGM to approve issuance of Bond of BDT 50.00 crore
The company has informed that the Board of Directors of the company in its 196th Meeting held on May 14, 2026 has decided to issue 25% Redeemable and 75% Convertible Coupon Bearing Bond of BDT 50.00 crore for 5 years to restructuring the company's loans subject to the approval from the shareholders of the Company in EGM and the approval from Bangladesh Securities and Exchange Commission (BSEC). (cont.) (cont. news of TECHNODRUG): Date of EGM: June 24, 2026 at 11.00 a.m. Record Date for EGM: June 10, 2026. Venue: Using Hybrid System in combination of Digital Platform through the link https://technodrug.hybridegmbd.net and Physical Presence at Institution of Diploma Engineers, 160/A, Kakrail VIP Road, Dhaka 1000. The Board of Directors has also decided to appoint MTB Capital Limited as the Issue Manager and Arranger for the proposed transaction. (end)
- Q3 Financials
(Q3 Un-audited): EPS was Tk. 0.31 for January-March 2026 as against Tk. 0.33 for January-March 2025; EPS was Tk. 1.18 for July 2025-March 2026 as against Tk. 1.41 for July 2024-March 2025. NOCFPS was Tk. 1.62 for July 2025-March 2026 as against Tk. 0.15 for July 2024-March 2025. NAV per share with revaluation was Tk. 31.38 as on March 31, 2026, and Tk. 30.58 as on June 30, 2025. NAV per share without revaluation was Tk. 27.69 as on March 31, 2026, and Tk. 26.88 as on June 30, 2025. (cont.) (Cont. news of TECHNODRUG): Reasons for significant deviation: The company's EPS has decreased due to lower sales revenue and increased financial expenses compare to the previous period. Net Cash Flow from operation (NOCFPS) increase due to decrease of paid to supplier and others. (end)
- Board Meeting schedule under LR 16(1)
As per Regulation 16(1) of the Dhaka Stock Exchange (Listing) Regulations, 2015, the Company has informed that a meeting of the Board of Directors will be held on April 29, 2026 at 5:30 pm to consider, among others, Un-Audited Financial Statements for the Third Quarter (Q3) period ended March 31, 2026.
- Appointment of Company Secretary
The Company has informed that the Board of Directors has appointed Mr. S. M. Abu Talha Siddik as the Company Secretary of the company with effect from March 15, 2026.
- Dividend Disbursement
The Company has informed that it has disbursed the Cash Dividend for the year ended June 30, 2025 to the respective shareholders.
- Category Change
The Company will be placed in 'A' category from existing 'Z' category with effect from February 15, 2026 as the Company has reported disbursement of 10% Cash Dividend for the year ended June 30, 2025.
- Category Change
The Company will be placed in 'Z' category from existing 'A' category with effect from February 05, 2026 as per provision 1(e) of BSEC Directive No. BSEC/CMRRCD/2009-193/77, dated May 20, 2024 regarding non-disbursement of the approved dividend within the stipulated time frame.
- Prohibition on providing loan facilities to purchase securities
The Stock Brokers and Merchant Bankers are requested to abstain from providing loan facilities to purchase securities of Techno Drugs Ltd. with effect from February 05, 2026 as per rule 11(8) of Bangladesh Securities and Exchange Commission (Margin) Rules, 2025.
- Auditor's report regarding status of IPO Proceeds utilization
Techno Drugs Limited submitted auditor's report regarding status of IPO (Initial Public Offering) Proceeds utilization statement for the quarter ended 31 December, 2025. To view the details, please visit: https://www.dsebd.org/Auditors_opinion/2025/TechnoDrugs_25.pdf
- Q2 Financials
(Q2 Un-audited): EPS was Tk. 0.40 for October-December 2025 as against Tk. 0.48 for October-December 2024; EPS was Tk. 0.87 for July-December 2025 as against Tk. 1.08 for July-December 2024. NOCFPS was Tk. 1.11 for July-December 2025 as against Tk. 0.19 for July-December 2024. NAV per share with revaluation was Tk. 31.08 as on December 31, 2025 and 30.58 as on June 30, 2025. NAV per share without revaluation was Tk. 27.38 as on December 31, 2025 and 26.88 as on June 30, 2025. (cont.) (Cont. news of TECHNODRUG): Reasons for deviations: EPS has decreased due to lower sales revenue and increased financial expenses compare to the previous period, NOCFPS increase due to decrease of paid to supplier and others. (end)
- Board Meeting schedule under LR 16(1)
As per Regulation 16(1) of the Dhaka Stock Exchange (Listing) Regulations, 2015, the Company has informed that a meeting of the Board of Directors will be held on January 31, 2026 at 4:00 PM to consider, among others, Un-Audited Financial Statements for the Second Quarter (Q2) period ended December 31, 2025.
Source: Dhaka Stock Exchange announcements. Some posts before 2014 have no title, and 2014–2020 coverage is incomplete.